Burkholderia cepacia complex

The Leeds Method of Management. April, 2008. Burkholderia cepacia complex [online]. Leeds Regional Adult and Paediatric Cystic Fibrosis Units, St James's University Hospital, Leeds, UK. Available from http://www.cysticfibrosismedicine.com

Introduction

The bacteriae previously known as ‘Burkholderia cepacia’ have been reclassified as nine closely related species, sometimes referred to as ‘genomovars’ (Table 1), (Coenye et al, 2001; Mahenthiralingam et al, 2002). Collectively these are commonly referred to as ‘Burkholderia cepacia complex’ (Bcc). The various genomovars have different pathogenic potential (Keig et al, 1999; Bevivino et al, 2002; Chu et al, 2002; Cystic Fibrosis Trust Infection Control Group, 2004).

Genomovar
Species
I
Burkholderia cepacia
II
Burkholderia multivorans
III
Burkholderia cenocepacia
IV
Burkholderia stabilis
V
Burkholderia vietnamiensis
VI
Burkholderia dolosa
VII
Burkholderia ambifaria
VIII
Burkholderia anthina
IX
Burkholderia pyrrocinia
Table 1. Taxonomy of the Burkholderia cepacia complex – genomovar status and species name
 

The prevalence of chronic respiratory infection with multiresistant Bcc increased in the 1980s and 1990s mainly due to hospital and social patient-to-patient transmission (Chen et al, 2001; Walsh et al, 2002). Further spread of Bcc infection has been very successfully interrupted by separating these patients from others attending the clinic. Some members of the complex are more closely associated with acute clinical deterioration (‘cepacia syndrome’) and patient-to-patient spread, in particular Burkholderia cenocepacia (Mahenthiralingam et al, 2001; Jones et al, 2004; Manno et al, 2004). Other species such as Burkholderia multivorans have also been associated with ‘cepacia syndrome’ (Blackburn et al, 2004) and some, such as Burkholderia dolosa appear as invasive in vitro as B. cenocepacia (Caraher et al, 2007). Chronic infection with B. dolosa has been associated with an accelerated decline in lung function (Kalish et al, 2006). Studies suggest that the epidemiology of Bcc has changed in recent years in CF Units. Successful segregation policies have resulted in a decline in the prevalence of B. cenocepacia and in many European CF Centres, including Leeds, the most common Bcc species is now B. multivorans (Brisse et al, 2004; De Boeck et al, 2004). Even in countries where B. cenocepacia remains the predominant species, such as the USA, most recent acquisitions have been with B. multivorans (Reik et al, 2005). Genotyping evidence also suggests that most isolates of B. multivorans appear largely unrelated between different patients, suggesting acquisition from the environment (Turton et al, 2003) rather than from other patients with CF. Isolates of Bcc can be found in environmental niches such as soil (LiPuma et al, 2002), although exactly how patients with CF acquire Bcc species such as B. multivorans remains uncertain.

Although the clinician is faced with an increasingly complex nomenclature for Bcc, it is important to remember that the genomovar classification alone cannot predict clinical outcome in any individual patient. Some patients infected with the same genomovar of Bcc may remain clinically stable, whereas others may experience a decline in lung function. It is also imperative that all patients with Bcc are strictly segregated from each other at all times, as some less virulent species may be replaced by highly virulent and transmissible species, such as B. cenocepacia (Mahenthiralingam et al, 2001).

As with P. aeruginosa, some isolates of Bcc, particularly B. multivorans, can be successfully eradicated with early aggressive antibiotic therapy before chronic infection becomes established (Etherington et al, 2003). We therefore treat all patients with new growths of Bcc with a regimen of three intravenous antibiotics (e.g. tobramycin plus meropenem plus ceftazidime) for two weeks followed by three consecutive months of nebulised TOBI®. There is also anecdotal evidence that eradication can be enhanced by giving aerosolised amiloride and tobramycin in combination (Middleton et al, 2005), a new strategy that we will pursue on a case-by-case basis.

Although in the laboratory the organism is often resistant to most intravenous antibiotics, most patients will respond to standard therapy (Peckham et al, 1994). A proportion of patients may have a more rapid decline in lung function. The reasons for this are unclear. There does not appear to be a greater inflammatory response to B. cepacia complex than to P. aeruginosa (Hendry et al, 1999). The optimum antibiotic treatment for ‘cepacia syndrome’ remains unclear and mortality unfortunately remains very high. However, survival has been described in a few patients following aggressive antibiotic therapy and in one case was associated with the use of steroids (Kazachkov et al, 2001; Weidmann et al, 2008)

Burkholderia cepacia complex and lung Tramsplant

Pre-operative infection with Bcc, particularly B. cenocepacia, is associated with a worse outcome. One and five year survival has been documented as 60% and 36% compared to 86% and 64% in non-Bcc infected patients (Egan et al, 2002). This high risk seems to relate to B. cenocepacia (genomovar III), infection exclusively (De Soyza et al, 2004; Meachery et al, 2008 ). The greatest danger to Bcc infected patients seems to be in the perioperative period. Beyond six months from the transplant the actuarial survival curves of Bcc infected patients and other patients with CF run parallel. Patients with Bcc infection have a poorer outcome (Meachery et al, 2008) and B. cenocepacia is now a contra-indication to lung transplantation as it is associated with such poor prognosis and post transplant sepsis.

 

Key points

• Bcc includes nine genomovars (different bacterial types) each with varying degrees of virulence

• Bcc genomovar classification alone cannot predict clinical outcome

• It is essential that patients with Bcc infection are isolated from other patients and from each other

• Early eradication may be possible

 

References

Bevivino A, Dalmastri C, Tabacchioni S, et al. Burkholderia cepacia complex bacteria from clinical and environmental sources in Italy: genomovar status and distribution of traits related to virulence and transmissibility. J Clin Microbiol 2002; 40: 846-851. [PubMed]

Blackburn L, Brownlee K, Conway S, et al. ’Cepacia syndrome’ with Burkholderia multivorans, nine years after initial colonization. J Cyst Fibros 2004; 3: 133-134 . [PubMed]

Brisse S, Cordevant C, Vandamme P, et al. Species distribution and ribotype diversity of Burkholderia cepacia complex isolates from French patients with cystic fibrosis. J Clin Microbiol 2004; 42: 4824-4827. [PubMed]

Caraher E, Duff C, Mullen T, et al. Invasion and biofilm formation of Burkholderia dolosa is comparable with Burkholderia cenocepacia and Burkholderia multivorans. J Cyst Fibros 2007; 6: 49-56. [PubMed]

Chen JS, Witzmann KA, Spilker T, et al. Endemicity and inter-city spread of Burkholderia cepacia genomovar III in cystic fibrosis. J Pediatr 2001; 139: 643-649. [PubMed]

Chu KK, Davidson DJ, Halsey TK, et al. Differential persistence among genomovars of the Burkholderia cepacia complex in a murine model of pulmonary infection. Infect Immun 2002; 70: 2715-2720. [PubMed]

Coenye T, Vandamme P, Govan JRW, et al. Taxonomy and identification of the Burkholderia cepacia complex. J Clin Microbiol 2001; 39: 3427-3436. [PubMed]

Cystic Fibrosis Trust Infection Control Group. The Burkholderia cepacia complex. Suggestions for Prevention and Infection Control. London. Cystic Fibrosis Trust, 2nd Edition, September 2004. [link]

De Boeck K, Malfroot A, Van Schil L, et al. Epidemiology of Burkholderia cepacia complex colonisation in cystic fibrosis patients. Eur Respir J 2004; 23: 851-856. [PubMed]

De Soyza A, Morris K, McDowell A, et al. Prevalence and clonality of Burkholderia cepacia complex genomovars in UK patients with cystic fibrosis referred for lung transplantation. Thorax 2004; 59: 526-528.

Egan TM, Detterbeck FC, Mill MR. Long term results of lung transplantation for cystic fibrosis. Eur J Cardiothorac Surg 2002; 22: 602-609.

Etherington C, Peckham DG, Conway SP, et al. Burkholderia cepacia complex infection in adults with cystic fibrosis – is early eradication possible? J Cyst Fibros 2003; 2: 220-221. [PubMed]

Hendry J, Elborn JS, Nixon L, et al. Cystic fibrosis: inflammatory response to infection with Burkholderia cepacia and Pseudomonas aeruginosa. Eur Respir J 1999; 14: 435-438. [PubMed]

Jones AM, Dodd ME, Govan JRW, et al. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax 2004; 59: 948-951. [PubMed]

Kalish LA, Waltz DA, Dovey M, et al. Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis. Am J Respir Crit Care Med 2006; 173: 421-425. [PubMed]

Kazachkov M, Lager J, LiPuma J, et al. Survival following Burkholderia cepacia sepsis in a patient with cystic fibrosis treated with corticosteroids. Pediatr Pulmonol 2001; 32: 338-340. [PubMed]

Keig PM, Ingham E, Vandamme P, et al. Differential invasion of respiratory epithelial cells by members of the Burkholderia cepacia complex. Pediatr Pulmonol 1999; Suppl 19: 270. [PubMed]

LiPuma JJ, Spilker T, Coenye T, et al. An epidemic Burkholderia cepacia complex strain identified in soil. Lancet 2002; 359: 2002-2003. [PubMed]

Mahenthiralingam E, Vandamme P, Campbell ME, et al. Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis 2001; 33: 1469-1475. [PubMed]

Mahenthiralingam E, Baldwin A, Vandamme P. Burkholderia cepacia complex infection in patients with cystic fibrosis. J Med Microbiol 2002; 51: 533-538. [PubMed]

Manno G, Dalmastri C, Tabacchioni S, et al. Epidemiology and clinical course of Burkholderia cepacia complex infections, particularly those caused by different Burkholderia cenocepacia strains, among patients attending an Italian cystic fibrosis center. J Clin Microbiol 2004; 42: 1491-1497. [PubMed]

Meachery G, De Soyza A, Nicholson A, et al. Outcomes of lung transplantation for cystic fibrosis in a large UK cohort.Thorax. 2008; 63: 725-731.

Middleton PG, Kidd TJ, Williams B. Combination aerosol therapy to treat Burkholderia cepacia complex. Eur Respir J 2005; 26: 305-308. [PubMed]

Peckham D, Crouch S, Humphreys H, et al. Effect of antibiotic treatment on inflammatory markers and lung function in cystic fibrosis patients with Pseudomonas cepacia. Thorax 1994; 49: 803-807. [PubMed]

Reik R, Spilker T, LiPuma JJ. Distribution of Burkholderia cepacia complex species among isolates recovered from persons with or without cystic fibrosis. J Clin Microbiol 2005; 43: 2926-2928. [PubMed]

Turton JF, Kaufmann ME, Mustafa N, et al. Molecular comparison of isolates of Burkholderia multivorans from patients with cystic fibrosis in the United Kingdom. J Clin Microbiol 2003; 41: 5750-5754. [PubMed]

Walsh NM, Casano AA, Manangan LP, et al. Risk factors for Burkholderia cepacia complex colonisation and infection among patients with cystic fibrosis. J Pediatr 2002; 141: 512-517. [PubMed]

Weidmann A, Webb AK, Dodd ME, et al. Successful treatment of cepacia syndrome with combination nebulised and intravenous antibiotic therapy. J Cyst Fibros. 2008;7: 409-411. [PubMed]

Copyright © cysticfibrosismedicine.com